Keywords: s-p, withdraws, cylatron, maa, drug, major, schering-plough
S-P withdraws Cylatron MAA
Article | 30 March 2009
US drug major Schering-Plough has withdrawn its application for a centralized marketing authorization for Cylatron (peginterferon alfa-2b), 200mcg/0.5ml, 300 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
